Document ID: chunk:federal_register_of_legislation:F2023L00941:reg:9:p6
Version: federal_register_of_legislation:F2023L00941
Segment Type: reg
Provision Reference: reg 9 (pt 6/6)
Character Range: 18312–19927

from the specified list of drugs at the time of the clinical worsening of peripheral neuropathy;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(56)      taking a drug which is associated in the individual with the clinical worsening of peripheral neuropathy during drug therapy and either:
(a)          the improvement of peripheral neuropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of peripheral neuropathy on rechallenge with the same drug or another drug from the same class of drugs; and
where the drug was being taken at the time of the clinical worsening of peripheral neuropathy;
(57)      being treated with cisplatin within the 6 months before the clinical worsening of peripheral neuropathy;
(58)      having bariatric surgery within the 5 years before the clinical worsening of peripheral neuropathy;
Note: bariatric surgery is defined in the Schedule 1 – Dictionary.
(59)      having vitamin B6 (pyridoxine) hypervitaminosis at the time of the clinical worsening of peripheral neuropathy;
Note: vitamin B6 (pyridoxine) hypervitaminosis is defined in the Schedule 1 – Dictionary.
(60)      undergoing stem cell or bone marrow transplantation before the clinical worsening of peripheral neuropathy;
(61)      having acute carbon monoxide poisoning, with a carboxyhaemoglobin level of over 20 percent, within the 30 days before the clinical worsening of peripheral neuropathy;
(62)      inability to obtain appropriate clinical management for peripheral neuropathy before the clinical worsening of peripheral neuropathy.